Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Generic version of Pfizer's CDK4,6 inhibitor launched

<< Previous

Bullboard Posts

Next >>

Comment by TitanBrawleron Jan 15, 2023 6:39pm

175 Views

Post# 35224533

RE:RE:RE:Generic version of Pfizer's CDK4,6 inhibitor launched

I wouldn't be surprised if this company gets a 100 billion dollar buyout.
This is a Golden opportunity to buy as much as possible.
Back up the truck...
Mortgage the house..
Get the golden goose that will make you a millionaire over night.
Big grin.

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management